Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
NRG Oncology
National Cancer Institute (NCI)
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
University of California, San Francisco
UNC Lineberger Comprehensive Cancer Center
Austrian Breast & Colorectal Cancer Study Group
Hoffmann-La Roche
Apexigen America, Inc.
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Loma Linda University
St. Jude Children's Research Hospital
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Barbara Ann Karmanos Cancer Institute
Genentech, Inc.
Hoffmann-La Roche
CEL-SCI Corporation
Radiation Therapy Oncology Group
Northwestern University
SCRI Development Innovations, LLC
Children's Oncology Group
Columbia University
Children's Oncology Group
Children's Oncology Group
Albert Einstein College of Medicine
Brown University
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Celgene
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
University of Pittsburgh
Ohio State University Comprehensive Cancer Center
Northwestern University
University of Kansas Medical Center
Hoffmann-La Roche